1.Sánchez G, Cervantes G y Maldonado J. Linfomas No Hodgkin. Med Int Mex 2004; 20: 111-23. 2.Estrada D, Rajdev L and Sparado J. Lymphoma, Non-Hodgkin. Emedicine. Last Updated: June 24, 2004. 3.Ng R, Better N, Green MD. Anticancer agents and cardiotoxicity. Semin Oncol. 2006; 33 (1): 2-14. 4.Youssef G, Links M. The prevention and management of cardiovascular complications of chemotherapy in patients with cancer. Am J Cardiovasc Drugs. 2005; 5 (4): 233-43. 5.Pasca A, Pereiro G, Mansilla S y Lastiri H. Toxicidad miocardiaca por antraciclinas. Rev Fed Arg Cardiol 2000; 29:319-325. 6.Suter T and Meier B. Detection of anthracycline- induced cardiotoxicity: is there light at the end of the tunnel?. Editorial. Annals of Oncology. 2002; 13: 647-649. 7.Cvetkovic RS, Scott LJ. Dexrazoxane a review of its use for cardioprotection during anthracycline chemotherapy. Drugs. 2005; 65 (7): 1005-24. 8.Gianni L, Haerman E, Lipshultz S, Minotti G, sarvazyan N and Sawyer D.Anthracycline Cardiotoxicity: From Bench to Bedside. J Clin Oncol 2008; 26: 3777-3784. 9.Yeh E, Tong A, Lenihan D, Yusuf W, Swafford J, Champion C et al. Cardiovascular Complications of Cancer Therapy: Diagnosis, Pathogenesis, and Management. Circulation 2004; 109: 3122-3131. 10.Marchandise B, Schroeder E, Bosly A, et al. Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics. Am Heart J. 1989; 118:92–98. 11.Ewer MS, Ali MK, Gibbs HR, et al. Cardiac diastolic function in pediatric patients receiving doxorubicin. Acta Oncol. 1994; 33:645–649. 12.Lipshultz SE, Rifai N, Sallan SE, et al. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation1997; 96:2641–2648. 13.Nousiainen T, Jantunen E, Vanninen E, et al. Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin’s lymphoma. Eur J Haematol. 1999; 62:135–141. 14.Meinardi MT, van Veldhuisen DJ, Gietema JA, et al. Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J Clin Oncol. 2001; 19: 2746–2753. 15.Moser EC, Noordijk EM, van Leeuwen FE, et al. Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma. Blood. 2006; 107: 2912-2919. 16.Losada R, Dorticós E, Porto DE, Abreu J, Valiente J, Espinosa E et al. Cardiotoxicidad en pacientes con leucemia aguda promielocítica tratados con altas dosis de antraciclinas. Rev Cubana Hematol Inmunol Hemoter 2003; 19 (2-3). 17.Hequet O, Le Q, Moullet I, Pauli E, Salles G, Espinouse D et al. Subclinical Late Cardiomyopathy After Doxorubicin Therapy for Lymphoma in Adults. Journal of Clinical Oncology 2004; 22 (10):1864-1871. 18.Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991; 324: 808-15. 19.Iarussi D, Galderisi M, Ratti G, Tedesco MA, Indolfi P, Casale F, et al. Left ventricular systolic and diastolic function after anthracycline chemotherapy in chilhood. Clin Cardiol 2001; 24(10):663-9. 20.Marty M, Espie M, Llombart A, Monnier A, Rapoport B and Stahalova V. Multicenter Randomized Phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastastic breast cancer patients treated wiht anthracycicline-based chemotherapy. Annals Oncology 2006; 17: 614-622. 21.Van Dalen E, Caron H, Dickinson H y Kremer L. Intervenciones cardioprotectoras para pacientes con cáncer que reciben antraciclinas. (Revisión Cochrane traducida). En Biblioteca Cochrane Plus, Número 3, 2008. Oxford, Update Sofwarw Ltd. Disponible en: http://www. Update-sofware-ltd de The Cochrane Library, Issue. Chichester, UK: John Wiley and Sonns, Ltd. 22.Xu X, Persson HL, Richardson DR. Molecular pharmacology of the interaction of anthracyclines with iron. Mol Pharmacol. 2005; 68 (2): 261-71. 23.Bernitsas E, Wei W, Mikol DD. Suppression of mitoxantrone cardiotoxicity in multiple sclerosis patients by dexrazoxane. Ann Neurol. 2006; 59(1):206-9. 24.Elbl L, Hrstkova H, Tomaskova I et al. Late anthracycline cardiotoxicity protection by dexrazoxane (ICRF-187) in pediatric patients: echocardiographic follow-up. Support Care Cancer. 2006; 14(2): 128-36. 25.Elbl L, Hrstkova H, Tomaskova I et al. Long-term serial echocardiographic examination of late anthracycline cardiotoxicity and its prevention by dexrazoxane in pediatric patients. Eur J Pediatr. 2005; 164(11): 678-84. 26.Galetta F, Franzoni F, Cervetti G et al. Effect of epirubicin-based chemotherapy and dexrazoxane supplementation on QT dispersion in non-Hodgkin lymphoma patients. Biomed Pharmacother. 2005; 59(10): 541-4. 27.Lipshultz SE, Rifai N, Dalton VM et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med. 2004; 351(2): 145-53. 28.Paiva MG, Petrilli AS, Moises VA et al. Cardioprotective effect of dexrazoxane during treatment with doxorubicin: a study using low-dose dobutamine stress echocardiography. Pediatr Blood Cancer. 2005; 45(7): 902-8. 29.Schuchter LM, Hensley ML, Meropol NJ, et al. 2002 update of recommendations for use of chemotherapy and radiotherapy protectants: Clinical practice guidelines of American Society of Clinical Oncology. J Clin Oncol 2002; 20: 2895-2903. 30.Giuseppe R, Luigi M. Hematologic Consequences of Renal Failure. Brenner and Rector’s. The Kidney, Sixth Edition 2000; 2079-2102. 31.Miyake T, Kung CK-H, Goldwasser E. Purification of human erythropoietin. J Biol Chem 1977; 252: 5558-5564. 32.Koury ST, Bondurat MC, Koury MJ. Localization of erythropoietin synthesizing cells in murine kidneys by in situ hybridisation. Blood 1988; 71:524-7. 33.Juul SE, Stallings SA, Christensen RD. Erythropoietin in the cerebrospinal fluid of neonates who sustained CNS injury. Pediatr Res 1999; 46: 543 547. 34.Juul SE, Anderson DK, Li Y, Christensen RD. Erythropoietin and erythropoietin receptor in the developing human central nervous system. Pediatr Res 1998; 43: 40 49. 35.Marti HH, Wenger RH, Rivas LA, Straumann U, Digicaylioglu M, Henn V et al. Erythropoietin gene expression in human, monkey and murine brain. Eur J Neurosci 1996; 8: 666 676. 36.Masuda S, Okano M, Yamagishi K, Nagao M, Ueda M, Sasaki R. A novel site of erythropoietin production. Oxygen-dependent production in cultured rat astrocytes. J Biol Chem 1994; 269: 19488-19493. 37.Riksen N, Hausenloy D and Yelon D. Erythropoietin: ready for prime-time cardioprotection. Treds in Pharmacological Sciences 29: 5: 258-267. Available on line 21 March 2008. 38.Chong ZZ and Maiese K. Erythropoietin involve the phosphatidylinositol 3-kinase pathway, 14-3-3 protein and FOXO3a nuclear trafficking to preserve endothelial cell integrity. British Journal of Pharmacology 2007; 150: 839-850. 39.Eschbach JW, Nelly MR, Haley NR, Abels RI, Adamson JW. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med 1989; 321: 158-163. 40.Goodnough LT, Monk TG, Andriole GL. Current concepts: erythropoietin theraphy. N Engl J Med 1997; 336: 933-938. 41.Allegro A, Galasso A, Siracusano L, Aloisi C, Corica F, Lagana A et al. Administration of recombinant erythropoietin determines increase of peripheral resistances in patients with hypovolemic shock. Nephron 1996; 74: 431-432. 42.Buemi M, Denuzzo G, Allegra A, Aloisi C, Squadrito F, Squadrito G et al. Recombinant human erythropoietin inhibits the cutaneous vasodilatation induced by acetyl-choline. Int J Microcirc 1995; 15: 283-286. 43.Buemi M, Allegra A, Aloisi C, Frisina N. Influence of therapy with recombinant erythropoietin on serum levels of neopterin in hemodialyzed subjects. Am J Nephrol 1991; 11: 281-283. 44.Kokot F, Wiecek A, Grzesczak W, Klepacka J, Klin M, Lao M. Influence of erythropoietin treatment on endocrine abnormalities in hemodialyzed patients. Contrib Nephrol 1989; 76: 257-270. 45.Moon, C. et al. Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc. Natl. Acad. Sci. U. S. A 2003; 100: 11612–11617. 46.Calvillo, L. et al. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc. Natl. Acad. Sci. U. S. A. 2003; 100: 4802–4806. 47.Parsa, C.J. et al. A novel protective effect of erythropoietin in the infarcted heart. J. Clin. Invest. 2003; 112: 999–1007. 48.Cai, Z. et al. Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury. Circulation 2003; 108: 79–85. 49.Tramontano, A.F. et al. Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochem. Biophys. Res. Commun. 2003; 308: 990–994. 50.Burger D. Erythropoietin protects cardiomyocytes from apoptosis via up-regulation of endothelial nitric oxide synthase. Cardiovasc. Res. 2006; 72: 51-59. 51.Toma C et al. Positive effect of darbepoetin on peri-infarction remodeling in a porcine model of myocardial ischemia-reperfusion. J. Mol. Cell. Cardiol. 2007; 43: 130-136. 52.Kristensen J. Et al. Lack ok acute cardiprotective effect from preischaemic Erythropoietin administration in aporcine coronary occlusion model. Clin. Physiol. Funct. Imaging 2005; 25: 305-310. 53.Olea F. Et al. High- dose Erythropoietin has no ling-term protective effects in sheep with reperfused myocardial infarction. J. Cardiovasc. Pharmacol. 2006; 47: 736-741. 54.Bullard AJ, Govewalla P, Yellon DM (2005). Erythropoietin protects the myocardium against reperfusion injury in vitro and in vivo. Basic Res Cardiol 100: 397–403. 55.Miki T, Miura T, Yano T, Takahashi A, Sakamoto J, Tanno M et al. (2006). Alteration in erythropoietin-induced cardioprotective signaling by postinfarct ventricular remodeling. J Pharmacol ExpTher 317: 68–75. 56.Chan C et al. Erythropoietin protects post-ischemic hearts by preventing extracellular matrix degradation: role of Jak-2-ERK pathway. Life Sci. 2007; 81: 717-723. 57.Parsa C et al. Cardioprotective effects of Erythropoietin in the reperfused ischemic heart: a potencial role for cardiac fibroblasts. J. Biol. Chem. 2004; 279: 20655-20662. 58.Rafiee P. Et al. Erythropoietin protects the infant heart against ischemia-reperfusion injury by triggering multiple signaling pathways. Basic Res. Cardio. 2005; 100: 187-197. 59.Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M, et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002; 8: 494-505. 60.Li L, Takemura G, Li Y, Miyata S, Esaki M, Okada H et al. Preventive Effect of Erythropoietin on Cardiac Dysfunction in Doxorubicin-Induced Cardiomyopathy. Circulation. 2006; 113:535-543. 61.Fu P and Arcasoy MO. Erythropoietin protects cardiac myocytes against anthracycline-induced apoptosis. Biochem Biophys Res Commun. 2007 March 9; 354(2): 372–378. 62.Donato H y Ferro H. Tratamiento con eritropoyetina humana recombinante. Medicina (B. Aires) v.66 n.1 Buenos Aires ene./feb. 2006. 63.Ehrenreich H, Aust C, Krampe H, Jahn H, Jacob S, Herrmann M, Sirén AL. Erythropoietin: Novel approaches to neuroprotection in human brain disease. Metabolic Brain Disease Dec 2004; 19 (3/4): 195-206. 64.Sirén AL, Fratelli M, Brines M, Goemans C, Casagrande S, Lewczuk P, et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci USA 2001; 98 (7): 4044-4049. 65.Chattopadhyay A, Choudhury TD, Bandyopadhyay D, Datta AG. Protective effect of erythropoietin on the oxidative damage of erythrocyte membrane by hydroxyl radical. Biochem Pharmacol 2000; 59:419–425. 66.Genc S, Akhisaroglu M, Kuralay F, Genc K. Erythropoietin restores glutathione peroxidase activity in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine-induced neurotoxicity in C57BL mice and stimulates murine astroglial glutathione peroxidase production in vitro. Neurosci Lett 2002; 321:73–76. 67.Agnello D, Bigini P, Villa P, Mennini T, Cerami A, Brines ML, Ghezzi P. Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis. Brain Res 2002; 952:128–134. 68.Villa P, Bigini P, Mennini T, Agnello D, Laragione T, Cagnotto A, et al. Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med 2003; 198(6):971–975. 69.Campana WM, Myers RR. Erythropoietin and erythropoietin receptors in the peripheral nervous system: Changes after nerve injury. Faseb J 2001; 15:1804–1806. 70.Sasaki R, Masuda S, Nagao M. Pleiotropic functions and tissue-specific expression of erythropoietin. News Physiol Sci 2001; 16:110–113. 71.Kawakami M, Sekiguchi M, Sato K, Kozaki S, Takahashi M. Erythropoietin receptor-mediated inhibition of exocytotic glutamate release confers neuroprotection during chemical ischemia. J Biol Chem 2001; 276:39469–39475. 72.Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C et al. From the cover: erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 2000; 19: 10526-31. 73.Bohlius J, Langensiepen S, Schwarzer G, Engert A. Epoetin in the treatment ofmalignant disease: A comprehensive meta-analysis. Blood 2002; 100:3430A. 74.Jelkmann W. Use of recombinant human erythropoietin as an antianemic and performance enhancing drug. Curr Pharm Biotechnol 2000; 1:11–31. 75.Goldberg N, Lundin AP, Delano B, Friedman EA, Stein RA (1992). Changes in left ventricular size, wall thickness, and function in anemic patients treated with recombinant human erythropoietin. Am Heart J 124: 424–427. 76.Chong ZZ, Kang JQ, Maiese K (2002). Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation 106: 2973–2979. 77.Chong ZZ, Kang JQ, Maiese K (2003a). Apaf-1, Bcl-xL, cytochrome c, and caspase-9 form the critical elements for cerebral vascular protection by erythropoietin. J Cereb Blood Flow Metab 23: 320–330. 78.Sakamaki K (2004). Regulation of endothelial cell death and its role in angiogenesis and vascular regression. Curr Neurovasc Res 1: 305–315. 79.George J, Goldstein E, Abashidze A, Wexler D, Hamed S, Shmilovich H et al. (2005). Erythropoietin promotes endothelial progenitor cell proliferative and adhesive properties in a PI 3-kinasedependent manner. Cardiovasc Res 68: 299–306. 80.Maiese K, Li F, Chong ZZ (2005). New avenues of exploration for erythropoietin. JAMA 293: 90–95. 81.Avasarala JR, Konduru SS (2005). Recombinant erythropoietin downregulates IL-6 and CXCR4 genes in TNF-alpha-treated primary cultures of human microvascular endothelial cells: implications for multiple sclerosis. J Mol Neurosci 25: 183–189. 82.Chong ZZ, Kang JQ, Maiese K (2003b). Erythropoietin fosters both intrinsic and extrinsic neuronal protection through modulation of microglia, Akt1, Bad, and caspase-mediated pathways. Br J Pharmacol 138: 1107–1118. 83.Chong ZZ, Li F, Maiese K (2005a). Erythropoietin requires NF-kappaB and its nuclear translocation to prevent early and late apoptotic neuronal injury during beta-amyloid toxicity. Curr Neurovasc Res 2: 387–399. 84.Silverberg DS, Wexler D, Blum M, Tchebiner JZ, Sheps D, Keren G et al. (2003). The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant 18: 141–146. 85.Ferrario M et al. Early Haemoglobin-independet increase of plasma erythropoietin levels in patients with acute myocardial infarction. Eur. Heart J. 2007; 28: 1805-1813. 86.Liem A et al. Effect of EPO administration on myocardial infarct size in patients with non-STE acute coronary syndromes; results from a pilot study. Int. J. Cardiol. (65). (in pres). 87.K Hellmann. Editorials. Preventing the cardiotoxicity of anthracyclines by dexrazoxane. A real breakthrough. BMJ 1999; 319: 1085-1086. 88.Informe Final del Ensayo Clínico: Impacto de la Eritropoyetina Humana Recombinante (ior? EPOCIM) en pacientes oncológicos portadores de anemia post-quimio y /o radioterapia. (5ta versión del protocolo). Datos no publicados. 89.Coleman T and Brines M. Science Review: Recombinat Human Erythopoietin in critical illness: a rol beyond anemia?. Critical Care 2004; 8 (5): 337-341. 90.Pérez-Oliva JF, Lagarde AM, Herrera R. Eficacia del tratamiento con eritropoyetina recombinante humana cubana (EPOCIM), en pacientes anémicos hemodializados. Rev Hab C Médicas 2004; 3 (10): 5-10. 91.Pérez-Oliva JF, Lagarde AM, Herrera R, Martínez AI, Raola ME, Magrans Ch. Broad Use of Cuban Recombinant Human Erythropoietin (ior-EPOCIM) in Dialysis Patients at the Institute of Nephrology. Medic Review 2005; VII (5). Disponible en: http://www.medicc.org/medicc_review/0505/cuban-medical-literature-2.html. 92.Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 1987 Jan 8; 316(2): 73-78. 93.Glaspy J, Bukowski R, Steinberg D et al. Impact of therapy with epoetin alpha on clinical outcome in patients with non-myeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 1997; 15:1218-34. 94.Littlewood TJ, Bajetta E, Nortier JW, et al. Effects of epoetin alfa on hematological parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized double blind, placebo-controlled trial. J Clin Oncol 2001; 19: 2865-74. 95.Rizzo JD, Lichtin AE, Woolf SH, Seidenfeld J, Bennett CL, Cella D, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 2002; 100(7): 2303-2320. 96.Witzig TE, Silberstein PT, Loprinzi CL, Sloan JA, Novotny PJ, Mailliard JA, et al. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 2005 Apr 20; 23(12):2606-17. 97.Nieder AM, Rosenblum n, Lepor H. Comparison of two different doses preoperative recombinant erythropoietin in men undergoing radical retropubic prostatectomy. Urology 2001; 57:737-41. 98.Goldberg MA, McCutchen JW, Jove M, Di Cesare P, Friedman RJ, Poss R et al. A safety and efficacy comparison study of two dosing regimens of epoetin alfa in patients undergoing major orthopedic surgery. Am J Orthop 1996; 25: 533- 42. 99.Stowell CP, Chandler H, Jove M, Guilfoyle M, Wacholtz MC. An open-label, ramdomized study to compare the safety and efficacy of perioperative epoetin alfa with preoperative autologous blood donation in total joint arthroplasty. Orthopedics 1999; 22 (Supl 1): 105-112. 100.“EPREX” Product Monograph 2005. Disponible en: http://www.janssen-ortho.com/JOI/pdf_files/Eprex_E.pdf. 101.Masuda S, Nagao M, Takahata K, Konishi Y, Gallyas F, Jr., Tabira T, Sasaki R: Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells. J Biol Chem 1993, 268: 11208-11216. 102.Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C, Itri LM, Cerami A: Erythropoietin crosses the bloodbrain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 2000, 97:10526-10531. 103.Agnello D, Bigini P, Villa P, Mennini T, Cerami A, Brines M, Ghezzi P: Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis. Brain Res 2002, 952:128. 104.Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Cotes PM. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 1986; ii: 1175-1178. 105.Mayer G, Thum J, Cada EM, Estummvol HK, Graf H. Working capacity is increased following recombinant human erythropoietin treatment. Kidney Int 1988; 34: 525-528. 106.Macdougall IC, Lewis NP, Saunders MJ, Cochlin DL, Davies ME, Hutton RD, et al. Exercise capacity, fistula blood flow and rheological studies during treatment with rHuEPO in haemodialysis patients. Nephrol Dial Transplant 1989; 4: 319. 107.Eschbach JW, Egrie JC, Downing MR, et al. The Use of Recombinant Human Erythropoietin (r-HuEPO): Effect in End-Stage Renal Disease (ESRD). In: Friedman, Beyer, De Santo, Giordano, eds. Prevention of Chronic Uremia. Philadelphia, PA: Field and Wood Inc; 1989:148-155. 108.Sosa I, García JD, Subirós N, González C, Rodríguez Y, García JC. Alternativa terapéutica en la isquemia cerebral empleando la Eritropoyetina Humana Recombinante (rHu-EPOCIM) como neuroprotector. Revista CNIC Ciencias Biológicas 2006 (en prensa). 109.García JC, Miranda J. Carta al editor. Rev. CENIC Ciencias Biológicas 2005; 36(2). 110.Sosa I, García JC, García JD, Subirós N, González C, Rodríguez Y, et al. Eritropoyetina humana recombinante (rHu-EPO CIM) por vía nasal como neuroprotector en el ICTUS. Libro resumen Congreso Caribeño de ICTUS, Santiago de Cuba, 2005. 111.Robert J. Anthracyclines: common pharmacologic features. En: Cvitokovic E, Droz JP, Armand JP, Khoury S, eds. Handbook of chemotherapy in clinical oncology (2.a ed.). Jersey, Channel Islands: Scientific Communication International Ltd, 1993; 268-276. 112.Bajetta E, Buzzoni R. Mitoxantrone. En: Cvitokovic E, Droz JP, Armand JP, Khoury S, eds. Handbook of chemotherapy in clinical oncology (2.a ed.), Jersey, Channel Islands: Scientific Communication International Ltd, 1993; 293-295. 113.Arlin ZA, Feldman EJ. Amsacrine. En: Cvitokovic E, Droz JP, Armand JP, Khoury S, eds. Handbook of chemotherapy in clinical oncology (2.a ed.), Jersey, Channel Islands: Scientific Communication International Ltd, 1993; 290-292. 114.Fleming TR. One-sample multiple testing procedures for Phase II clinical trials. Biometrics. 1982; 38: 143-151. 115.Marc Buyse. Randomized designs for early trials of new cancer treatments- an overview. Drug Information Journal, Vol. 34, pp. 387–396, 2000.